Advertisement

Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study

  • Christian HöchtEmail author
  • Carla Di Verniero
  • Javier A. W. Opezzo
  • Guillermo F. Bramuglia
  • Carlos A. Taira
Original Article

Abstract

The present work addressed possible alterations in the pharmacokinetics and the in vivo pharmacodynamic of metoprolol (MET) in spontaneously hypertensive (SH) rats and Wistar Kyoto (WKY) animals by means of the microdialysis technique. The correlation between MET unbound plasma concentrations and its pharmacological effects, such as heart rate and blood pressure change, was also examined in SH and WKY rats by the application of a PK-PD model. MET dialysate concentrations and its chronotropic and blood pressure effect were determined during 3 h after the administration of 3 and 10 mg.kg−1 of the drug. A PK-PD model with a separate effect compartment was used to analyse the data. A good correlation between plasma MET concentrations and its hypotensive and chronotropic effect was found in all experimental groups. Although a greater maximal effect (Emax) for the antihypertensive effect of MET was observed in SH rats (WKY: Emax: −17±1 mmHg; SH: Emax: −28±4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC50) comparing SH (IC50: 583±146 ng.ml−1) and WKY animals (IC50: 639±187 ng.ml−1). The bradycardic effect of MET was greater in SH rats (Emax: −29±1%, P<0.05 versus WKY rats) than in WK animals (Emax: −22±2%), but no differences were observed in the IC50 comparing both experimental groups (WKY: IC50: 187±53 ng.ml−1; SH: IC50: 216±62 ng.ml−1). Pharmacokinetic analysis shows that the volume of distribution of MET was greater in SH rats (Vd: 3.4±0.5 l, P<0.05 versus WKY rats) with regard to Wistar Kyoto (WKY) animals (Vd: 1.9±0.2 l). The results suggest that the pharmacokinetic behaviour of metoprolol are modified in SH rats, resulting in an increased volume of distribution. A greater maximal efficacy to the hypotensive effect of metoprolol was observed in SH rats, suggesting participation of β-adrenoceptors in the maintenance of the hypertension. Also, a greater chronotropic response to metoprolol was found in the hypertensive group compared with WKY animals, suggesting that, at least in part, the greater cardiac effect of metoprolol explained the enhanced hypotensive response of the beta blocker in the SH animals.

Keywords

Spontaneously hypertension Microdialysis Pharmacokinetic-pharmacodynamic modeling Metoprolol Chronotropic effect Blood pressure 

Notes

Acknowledgements

This work was supported by a grant from Secretaría de Ciencia y Técnica, Universidad de Buenos Aires, Argentina.

Dr. Carlos A. Taira is member of Carrera del Investigador, CONICET, Argentina.

References

  1. Abboud FM (1982) The sympathetic system in hypertension. State-of-the-art review. Hypertension 4(3 Pt 2):208–225PubMedGoogle Scholar
  2. Adams MA, Bobik A, Korner PI (1989) Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function. Hypertension 14:191–202PubMedGoogle Scholar
  3. Antonaccio MJ, High J, DeForrest JM, Sybertz E (1986) Antihypertensive effects of 12 beta adrenoceptor antagonists in conscious spontaneously hypertensive rats: relationship to changes in plasma renin activity, heart rate and sympathetic nerve function. J Pharmacol Exp Ther 238:378–387PubMedGoogle Scholar
  4. Benveniste H, Huttemeier PC (1990) Microdialysis—theory and application. Prog Neurobiol 33:195–215CrossRefGoogle Scholar
  5. Brynne L, Karlsson MO, Paalzow LK (1998) Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia. J Pharmacol Exp Ther 286:1152–1158PubMedGoogle Scholar
  6. Buckingham RE, Hamilton TC (1980) Comparison of the anti-hypertensive response to beta-adrenoceptor blocking drugs in intact and adrenal-demedullated spontaneously hypertensive rats. Br J Pharmacol 68:667–676PubMedGoogle Scholar
  7. Chen Z, Steger RW (1993) Plasma microdialysis. A technique for continuous plasma sampling in freely moving rats. J Pharmacol Toxicol Meth 29:111–118CrossRefGoogle Scholar
  8. Chiappe de Cingolani GE (1988) Adipocyte responsiveness to norepinephrine in spontaneoulsy hypertensive rats. Metabolism 37:318–322PubMedCrossRefGoogle Scholar
  9. Conway FJ, Fitzgerald JD, Mcainsh J, Rowlands DJ, Simpson WT (1976) Human pharmacokinetic and pharmacodynamic studies of atenolol, a new cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol 42:665P–666PGoogle Scholar
  10. Elmquist WF, Sawchuk RJ (1997) Application of microdialysis in pharmacokinetic studies. Pharm Res 14:267–287PubMedCrossRefGoogle Scholar
  11. Esler M, Zweifler A, Randall O, DeQuattro V (1977) Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol. Clin Pharmacol Ther 22:299–308PubMedGoogle Scholar
  12. Flockhart DA, Tanus-Santos JE (2002) Implication of cytochrome P-450 interactions when prescribing medication for hypertension. Arch Int Med 162:405–412CrossRefGoogle Scholar
  13. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
  14. Giles T (2006) Circadian rhythm of blood pressure and the relation to cardiovascular events. J Hypertens 24(suppl 2):S11–S16CrossRefGoogle Scholar
  15. Grassi G (1998) Role of the sympathetic nervous system in human hypertension. J Hypertens 16:1979–1987PubMedCrossRefGoogle Scholar
  16. Hajri T, Ibrahimi A, Coburn CT, Knapp FF, Kurtz T, Praveneci M, Abumrad NA (2001) Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem 276:23661–23666PubMedCrossRefGoogle Scholar
  17. Höcht C, Di Verniero C, Opezzo JAW, Taira CA (2004a) Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. Naunyn-Schmiedeberg’s Arch Pharmacol 370:1–8CrossRefGoogle Scholar
  18. Höcht C, Opezzo JAW, Taira CA (2004b) Pharmacokinetics and the cardiovascular effects of irbesartan in aortic coarctated rats. Pharmacology 70:23–30PubMedCrossRefGoogle Scholar
  19. Höcht C, Di Verniero C, Opezzo JAW, Taira CA (2005) Applicability of microdialysis as a technique for pharmacokinetic pharmacodynamic (PK-PD) modeling of antihypertensive beta-blockers. J Pharmacol Toxicol Meth 52:244–250CrossRefGoogle Scholar
  20. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN (2004) Comparative pharmacology of human β-adrenergic receptor subtypes—characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg’s Arch Pharmacol 369:151–159CrossRefGoogle Scholar
  21. Kendall MJ, Brown D, Grieve A (1977) Pharmacokinetic and pharmacodynamic studies of a single oral doses of metoprolol in normal volunteers. Eur J Drug Metab Pharmacokinet 2:73–80CrossRefGoogle Scholar
  22. Leonetti G, Mayer G, Morganti A, Terzoli L, Zanchetti A, Bianchetti G, Di Salle E, Morselli PL, Chidsey CA (1975) Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med 48:491–499Google Scholar
  23. Meredith PA (1997) Clinical relevance of optimal pharmacokinetics in the treatment of hypertension. J Hypertens 15(suppl 5):S27–S31Google Scholar
  24. Mostafavi SA, Foster RT (2000) Pharmacokinetics of metoprolol enantiomers following single and multiple administration of racemate in rat. Int J Pharm 202:97–102PubMedCrossRefGoogle Scholar
  25. Myers MG, Thiessen JJ (1980) Metoprolol kinetics and dose response in hypertensive patients. Clin Pharmacol Ther 27:756–762PubMedCrossRefGoogle Scholar
  26. Nelson KM, Sheperd RE, Spitzer JA (1987) Lipolysis and beta-adrenergic receptor binding on adipocytes of spontaneoulsy hypertensive rats. Biochem Med Metab Biol 37:51–60PubMedCrossRefGoogle Scholar
  27. Oates JA, Brown NJ (2001) Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, Gilman A (eds) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw Hill, New York, pp 871–900Google Scholar
  28. Opezzo JAW, Höcht C, Taira CA, Bramuglia GF (2001) Pharmacokinetic study of methyldopa in aortic coarctated rats using a microdialysis technique. Pharmacol Res 43:155–159PubMedCrossRefGoogle Scholar
  29. Sklar J, Johnston D, Overlie P, Gerber JG, Brammell HL, Gal J, Nies AS (1982) The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men. Circulation 65:894–899PubMedGoogle Scholar
  30. Spitzer JA, Burns AH, O’Malley PJ (1985) Catecholamine-stimulated lipolysis in adipocytes of spontaneously hypertensive rats. Biochem Med 34:100–106PubMedCrossRefGoogle Scholar
  31. Ståhle L (1992) Pharmacokinetic estimations from microdialysis data. Eur J Clin Pharmacol 43:289–294PubMedCrossRefGoogle Scholar
  32. Toutain PL (2002) Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. AAPS Pharm Sci 4:1–29CrossRefGoogle Scholar
  33. Tsoporis J, Leenen FH (1988) Effect of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension 11:376–386PubMedGoogle Scholar
  34. Ungerstedt U (1991) Microdialysis-principles and applications for studies in animals and man. J Int Med 230:365–373CrossRefGoogle Scholar
  35. von Bahr C, Collste P, Frisk-Holmberg M, Haglund K, Orme M, Ostman J, Sjoqvist F (1976) Plasma levels and effects of metoprolol on blood pressure, adrenergic beta receptor blockade and plasma renin activity in essential hypertension. Clin Pharmacol Ther 20:130–137Google Scholar
  36. Yin XX, Zhang YD, Luo JP, Huang XP, Shen JP, Ding Y, Huang DK (1997) Pharmacokinetic-pharmacodynamic modeling of metoprolol stereoisomers in spontaneously hypertensive rat. Zhongguo Yao Li Xue Bao 18:104–108PubMedGoogle Scholar
  37. Zacest R, Koch-Weser J (1972) Relation of propranolol plasma levels to β-blockade during oral therapy. Pharmacology 7:178–184PubMedCrossRefGoogle Scholar
  38. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol 369:23–37CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Christian Höcht
    • 1
    Email author
  • Carla Di Verniero
    • 1
  • Javier A. W. Opezzo
    • 1
  • Guillermo F. Bramuglia
    • 1
  • Carlos A. Taira
    • 1
  1. 1.Cátedra de Farmacología, Facultad de Farmacia y BioquímicaUniversidad de Buenos AiresBuenos AiresArgentina

Personalised recommendations